Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Colorcon
Harvard Business School
Baxter
Novartis
Farmers Insurance
Teva
McKesson
Deloitte
Argus Health

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202240

« Back to Dashboard

NDA 202240 describes CELECOXIB, which is a drug marketed by Alembic Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Cipla Ltd, Jubilant Generics, Lupin Ltd, Macleods Pharms Ltd, Mylan Pharms Inc, Teva, Torrent Pharms Ltd, and Watson Labs Inc, and is included in eleven NDAs. It is available from forty suppliers. Additional details are available on the CELECOXIB profile page.

The generic ingredient in CELECOXIB is celecoxib. There are twenty-six drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the celecoxib profile page.
Summary for 202240
Tradename:CELECOXIB
Applicant:Lupin Ltd
Ingredient:celecoxib
Patents:0
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 202240
Medical Subject Heading (MeSH) Categories for 202240
Suppliers and Packaging for NDA: 202240
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CELECOXIB celecoxib CAPSULE;ORAL 202240 ANDA Lupin Pharmaceuticals, Inc. 68180-395 68180-395-07 60 CAPSULE in 1 BOTTLE (68180-395-07)
CELECOXIB celecoxib CAPSULE;ORAL 202240 ANDA Lupin Pharmaceuticals, Inc. 68180-396 68180-396-03 1000 CAPSULE in 1 BOTTLE (68180-396-03)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength50MG
Approval Date:Oct 29, 2014TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength100MG
Approval Date:Jun 9, 2015TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength200MG
Approval Date:Jun 9, 2015TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Farmers Insurance
McKesson
Accenture
Teva
Deloitte
Baxter
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot